Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...

The fallout for Venture Global Inc., in the wake of a troubled initial public offering, accelerated amid a market selloff ...

Even so the deal solidifies Venture Global’s place in the public markets with an impressive $50 billion market cap. And it ...

HistoSonics Inc., a medical device company whose backers include Johnson & Johnson’s venture capital arm, is weighing a US ...

Venture Global's IPO represents a test for investor appetite for fossil fuel projects in the Trump administration.

Rexpro Enterprises IPO shows a grey market premium of ₹10, indicating a potential listing price of ₹155. The IPO was ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...

The stock market trading debut comes as incoming President Trump has said he plans to boost America’s energy production.

More generally, markets have a way of recalibrating, and Venture Global’s IPO offers a nuanced lesson. It’s a reminder that valuations aren’t fixed by management or banker decree, but rather hammered ...

Steel products maker Colform Group Bhd’s initial public offering (IPO) of 30 million shares has been oversubscribed by 41.82 ...